91 datasets found
  1. COVID-19 cases and deaths per million in 210 countries as of July 13, 2022

    • statista.com
    Updated Nov 25, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2024). COVID-19 cases and deaths per million in 210 countries as of July 13, 2022 [Dataset]. https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/
    Explore at:
    Dataset updated
    Nov 25, 2024
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    Worldwide
    Description

    Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

    The difficulties of death figures

    This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

    Where are these numbers coming from?

    The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

  2. COVID-19 death rates in 2020 countries worldwide as of April 26, 2022

    • statista.com
    Updated Apr 15, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2022). COVID-19 death rates in 2020 countries worldwide as of April 26, 2022 [Dataset]. https://www.statista.com/statistics/1105914/coronavirus-death-rates-worldwide/
    Explore at:
    Dataset updated
    Apr 15, 2022
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    Worldwide
    Description

    COVID-19 rate of death, or the known deaths divided by confirmed cases, was over ten percent in Yemen, the only country that has 1,000 or more cases. This according to a calculation that combines coronavirus stats on both deaths and registered cases for 221 different countries. Note that death rates are not the same as the chance of dying from an infection or the number of deaths based on an at-risk population. By April 26, 2022, the virus had infected over 510.2 million people worldwide, and led to a loss of 6.2 million. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

    Where are these numbers coming from?

    The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. Note that Statista aims to also provide domestic source material for a more complete picture, and not to just look at one particular source. Examples are these statistics on the confirmed coronavirus cases in Russia or the COVID-19 cases in Italy, both of which are from domestic sources. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

    A word on the flaws of numbers like this

    People are right to ask whether these numbers are at all representative or not for several reasons. First, countries worldwide decide differently on who gets tested for the virus, meaning that comparing case numbers or death rates could to some extent be misleading. Germany, for example, started testing relatively early once the country’s first case was confirmed in Bavaria in January 2020, whereas Italy tests for the coronavirus postmortem. Second, not all people go to see (or can see, due to testing capacity) a doctor when they have mild symptoms. Countries like Norway and the Netherlands, for example, recommend people with non-severe symptoms to just stay at home. This means not all cases are known all the time, which could significantly alter the death rate as it is presented here. Third and finally, numbers like this change very frequently depending on how the pandemic spreads or the national healthcare capacity. It is therefore recommended to look at other (freely accessible) content that dives more into specifics, such as the coronavirus testing capacity in India or the number of hospital beds in the UK. Only with additional pieces of information can you get the full picture, something that this statistic in its current state simply cannot provide.

  3. Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status

    • data.cdc.gov
    • data.virginia.gov
    • +1more
    application/rdfxml +4
    Updated Feb 22, 2023
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    CDC COVID-19 Response, Epidemiology Task Force (2023). Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status [Dataset]. https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a
    Explore at:
    tsv, application/rssxml, csv, application/rdfxml, xmlAvailable download formats
    Dataset updated
    Feb 22, 2023
    Dataset provided by
    Centers for Disease Control and Preventionhttp://www.cdc.gov/
    Authors
    CDC COVID-19 Response, Epidemiology Task Force
    Description

    Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

    Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

    Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

  4. COVID-19 cases and deaths in Mexico 2025

    • statista.com
    Updated Jun 5, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). COVID-19 cases and deaths in Mexico 2025 [Dataset]. https://www.statista.com/statistics/1107063/mexico-covid-19-cases-deaths/
    Explore at:
    Dataset updated
    Jun 5, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    Mar 1, 2020 - May 11, 2025
    Area covered
    Mexico
    Description

    The first case of COVID-19 in Mexico was detected on March 1, 2020. By the end of the year, the total number of confirmed infections had surpassed 1.4 million. Meanwhile, the number of deaths related to the disease was nearing 148,000. On May 11, 2025, the number of cases recorded had reached 7.6 million, while the number of deaths amounted to around 335,000. The relevance of the Omicron variant Omicron, a highly contagious COVID-19 variant, was declared of concern by the World Health Organization (WHO) at the end of November 2021. As the pandemic unfolded, it became the variant with the highest share of COVID-19 cases in the world. In Latin America, countries such as Colombia, Argentina, Brazil, and Mexico were strongly affected. In fact, by 2023 nearly all analyzed sequences within these countries corresponded to an Omicron subvariant. Beyond a health crisis As the COVID-19 pandemic progressed worldwide, the respiratory disease caused by the virus SARS-CoV-2 virus first detected in Wuhan brought considerable economic consequences for countries and households. While Mexico’s gross domestic product (GDP) in current prices declined in 2020 compared to the previous year, a survey conducted among adults during the first months of 2021 showed COVID-19 impacted families mainly through finances and employment, with around one third of households in Mexico reporting an income reduction and the same proportion having at least one household member suffering from the disease.Find the most up-to-date information about the coronavirus pandemic in the world under Statista’s COVID-19 facts and figures site.

  5. f

    Table_2_Decrease in COVID-19 adverse outcomes in adults during the Delta and...

    • frontiersin.figshare.com
    docx
    Updated Jun 2, 2023
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Lenin Domínguez-Ramírez; Itzel Solis-Tejeda; Jorge Ayon-Aguilar; Antonio Mayoral-Ortiz; Francisca Sosa-Jurado; Rosana Pelayo; Gerardo Santos-López; Paulina Cortes-Hernandez (2023). Table_2_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx [Dataset]. http://doi.org/10.3389/fpubh.2022.1010256.s003
    Explore at:
    docxAvailable download formats
    Dataset updated
    Jun 2, 2023
    Dataset provided by
    Frontiers
    Authors
    Lenin Domínguez-Ramírez; Itzel Solis-Tejeda; Jorge Ayon-Aguilar; Antonio Mayoral-Ortiz; Francisca Sosa-Jurado; Rosana Pelayo; Gerardo Santos-López; Paulina Cortes-Hernandez
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Mexico, one of the countries severely affected by COVID-19, accumulated more than 5. 1 all-cause excess deaths/1,000 inhabitants and 2.5 COVID-19 confirmed deaths/1,000 inhabitants, in 2 years. In this scenario of high SARS-CoV-2 circulation, we analyzed the effectiveness of the country's vaccination strategy that used 7 different vaccines from around the world, and focused on vaccinating the oldest population first. We analyzed the national dataset published by Mexican health authorities, as a retrospective cohort, separating cases, hospitalizations, deaths and excess deaths by wave and age group. We explored if the vaccination strategy was effective to limit severe COVID-19 during the active outbreaks caused by Delta and Omicron variants. Vaccination of the eldest third of the population reduced COVID-19 hospitalizations, deaths and excess deaths by 46–55% in the third wave driven by Delta SARS-CoV-2. These adverse outcomes dropped 74–85% by the fourth wave driven by Omicron, when all adults had access to vaccines. Vaccine access for the pregnant resulted in 85–90% decrease in COVID-19 fatalities in pregnant individuals and 80% decrease in infants 0 years old by the Omicron wave. In contrast, in the rest of the pediatric population that did not access vaccination before the period analyzed, COVID-19 hospitalizations increased >40% during the Delta and Omicron waves. Our analysis suggests that the vaccination strategy in Mexico has been successful to limit population mortality and decrease severe COVID-19, but children in Mexico still need access to SARS-CoV-2 vaccines to limit severe COVID-19, in particular those 1–4 years old.

  6. f

    Data_Sheet_2_A global analysis of COVID-19 infection fatality rate and its...

    • frontiersin.figshare.com
    docx
    Updated Jun 2, 2023
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Nhi Thi Hong Nguyen; Tsong-Yih Ou; Le Duc Huy; Chung-Liang Shih; Yao-Mao Chang; Thanh-Phuc Phan; Chung-Chien Huang (2023). Data_Sheet_2_A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study.docx [Dataset]. http://doi.org/10.3389/fpubh.2023.1145138.s002
    Explore at:
    docxAvailable download formats
    Dataset updated
    Jun 2, 2023
    Dataset provided by
    Frontiers
    Authors
    Nhi Thi Hong Nguyen; Tsong-Yih Ou; Le Duc Huy; Chung-Liang Shih; Yao-Mao Chang; Thanh-Phuc Phan; Chung-Chien Huang
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    BackgroundThe Omicron variant of SARS-CoV-2 is more highly infectious and transmissible than prior variants of concern. It was unclear which factors might have contributed to the alteration of COVID-19 cases and deaths during the Delta and Omicron variant periods. This study aimed to compare the COVID-19 average weekly infection fatality rate (AWIFR), investigate factors associated with COVID-19 AWIFR, and explore the factors linked to the increase in COVID-19 AWIFR between two periods of Delta and Omicron variants.Materials and methodsAn ecological study has been conducted among 110 countries over the first 12 weeks during two periods of Delta and Omicron variant dominance using open publicly available datasets. Our analysis included 102 countries in the Delta period and 107 countries in the Omicron period. Linear mixed-effects models and linear regression models were used to explore factors associated with the variation of AWIFR over Delta and Omicron periods.FindingsDuring the Delta period, the lower AWIFR was witnessed in countries with better government effectiveness index [β = −0.762, 95% CI (−1.238)–(−0.287)] and higher proportion of the people fully vaccinated [β = −0.385, 95% CI (−0.629)–(−0.141)]. In contrast, a higher burden of cardiovascular diseases was positively associated with AWIFR (β = 0.517, 95% CI 0.102–0.932). Over the Omicron period, while years lived with disability (YLD) caused by metabolism disorders (β = 0.843, 95% CI 0.486–1.2), the proportion of the population aged older than 65 years (β = 0.737, 95% CI 0.237–1.238) was positively associated with poorer AWIFR, and the high proportion of the population vaccinated with a booster dose [β = −0.321, 95% CI (−0.624)–(−0.018)] was linked with the better outcome. Over two periods of Delta and Omicron, the increase in government effectiveness index was associated with a decrease in AWIFR [β = −0.438, 95% CI (−0.750)–(−0.126)]; whereas, higher death rates caused by diabetes and kidney (β = 0.472, 95% CI 0.089–0.855) and percentage of population aged older than 65 years (β = 0.407, 95% CI 0.013–0.802) were associated with a significant increase in AWIFR.ConclusionThe COVID-19 infection fatality rates were strongly linked with the coverage of vaccination rate, effectiveness of government, and health burden related to chronic diseases. Therefore, proper policies for the improvement of vaccination coverage and support of vulnerable groups could substantially mitigate the burden of COVID-19.

  7. f

    Data_Sheet_1_A global analysis of COVID-19 infection fatality rate and its...

    • datasetcatalog.nlm.nih.gov
    • frontiersin.figshare.com
    Updated Jun 2, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Phan, Thanh-Phuc; Chang, Yao-Mao; Huy, Le Duc; Ou, Tsong-Yih; Nguyen, Nhi Thi Hong; Huang, Chung-Chien; Shih, Chung-Liang (2023). Data_Sheet_1_A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study.docx [Dataset]. https://datasetcatalog.nlm.nih.gov/dataset?q=0001018796
    Explore at:
    Dataset updated
    Jun 2, 2023
    Authors
    Phan, Thanh-Phuc; Chang, Yao-Mao; Huy, Le Duc; Ou, Tsong-Yih; Nguyen, Nhi Thi Hong; Huang, Chung-Chien; Shih, Chung-Liang
    Description

    BackgroundThe Omicron variant of SARS-CoV-2 is more highly infectious and transmissible than prior variants of concern. It was unclear which factors might have contributed to the alteration of COVID-19 cases and deaths during the Delta and Omicron variant periods. This study aimed to compare the COVID-19 average weekly infection fatality rate (AWIFR), investigate factors associated with COVID-19 AWIFR, and explore the factors linked to the increase in COVID-19 AWIFR between two periods of Delta and Omicron variants.Materials and methodsAn ecological study has been conducted among 110 countries over the first 12 weeks during two periods of Delta and Omicron variant dominance using open publicly available datasets. Our analysis included 102 countries in the Delta period and 107 countries in the Omicron period. Linear mixed-effects models and linear regression models were used to explore factors associated with the variation of AWIFR over Delta and Omicron periods.FindingsDuring the Delta period, the lower AWIFR was witnessed in countries with better government effectiveness index [β = −0.762, 95% CI (−1.238)–(−0.287)] and higher proportion of the people fully vaccinated [β = −0.385, 95% CI (−0.629)–(−0.141)]. In contrast, a higher burden of cardiovascular diseases was positively associated with AWIFR (β = 0.517, 95% CI 0.102–0.932). Over the Omicron period, while years lived with disability (YLD) caused by metabolism disorders (β = 0.843, 95% CI 0.486–1.2), the proportion of the population aged older than 65 years (β = 0.737, 95% CI 0.237–1.238) was positively associated with poorer AWIFR, and the high proportion of the population vaccinated with a booster dose [β = −0.321, 95% CI (−0.624)–(−0.018)] was linked with the better outcome. Over two periods of Delta and Omicron, the increase in government effectiveness index was associated with a decrease in AWIFR [β = −0.438, 95% CI (−0.750)–(−0.126)]; whereas, higher death rates caused by diabetes and kidney (β = 0.472, 95% CI 0.089–0.855) and percentage of population aged older than 65 years (β = 0.407, 95% CI 0.013–0.802) were associated with a significant increase in AWIFR.ConclusionThe COVID-19 infection fatality rates were strongly linked with the coverage of vaccination rate, effectiveness of government, and health burden related to chronic diseases. Therefore, proper policies for the improvement of vaccination coverage and support of vulnerable groups could substantially mitigate the burden of COVID-19.

  8. Age comparison of COVID-19 fatality rate South Korea 2023

    • statista.com
    Updated Jun 4, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2024). Age comparison of COVID-19 fatality rate South Korea 2023 [Dataset]. https://www.statista.com/statistics/1105088/south-korea-coronavirus-mortality-rate-by-age/
    Explore at:
    Dataset updated
    Jun 4, 2024
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    Aug 28, 2023
    Area covered
    South Korea
    Description

    As of August 28, 2023, the fatality rate of novel coronavirus (COVID-19) in South Korea stood at around 1.7 percent among people aged 80 year and older. This made them the most vulnerable age group, followed by people in their seventies. After the first wave lasted till April and the second wave in August 2020, Korea faced a fourth wave fueled by the delta and omicron variants in 2022.

    For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

  9. Covid19 Global Excess Deaths (daily updates)

    • kaggle.com
    Updated Aug 7, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Joakim Arvidsson (2025). Covid19 Global Excess Deaths (daily updates) [Dataset]. https://www.kaggle.com/datasets/joebeachcapital/covid19-global-excess-deaths-daily-updates/versions/648
    Explore at:
    CroissantCroissant is a format for machine-learning datasets. Learn more about this at mlcommons.org/croissant.
    Dataset updated
    Aug 7, 2025
    Dataset provided by
    Kagglehttp://kaggle.com/
    Authors
    Joakim Arvidsson
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Daily updates of Covid-19 Global Excess Deaths from the Economist's GitHub repository: https://github.com/TheEconomist/covid-19-the-economist-global-excess-deaths-model

    Interpreting estimates

    Estimating excess deaths for every country every day since the pandemic began is a complex and difficult task. Rather than being overly confident in a single number, limited data means that we can often only give a very very wide range of plausible values. Focusing on central estimates in such cases would be misleading: unless ranges are very narrow, the 95% range should be reported when possible. The ranges assume that the conditions for bootstrap confidence intervals are met. Please see our tracker page and methodology for more information.

    New variants

    The Omicron variant, first detected in southern Africa in November 2021, appears to have characteristics that are different to earlier versions of sars-cov-2. Where this variant is now dominant, this change makes estimates uncertain beyond the ranges indicated. Other new variants may do the same. As more data is incorporated from places where new variants are dominant, predictions improve.

    Non-reporting countries

    Turkmenistan and the Democratic People's Republic of Korea have not reported any covid-19 figures since the start of the pandemic. They also have not published all-cause mortality data. Exports of estimates for the Democratic People's Republic of Korea have been temporarily disabled as it now issues contradictory data: reporting a significant outbreak through its state media, but zero confirmed covid-19 cases/deaths to the WHO.

    Acknowledgements

    A special thanks to all our sources and to those who have made the data to create these estimates available. We list all our sources in our methodology. Within script 1, the source for each variable is also given as the data is loaded, with the exception of our sources for excess deaths data, which we detail in on our free-to-read excess deaths tracker as well as on GitHub. The gradient booster implementation used to fit the models is aGTBoost, detailed here.

    Calculating excess deaths for the entire world over multiple years is both complex and imprecise. We welcome any suggestions on how to improve the model, be it data, algorithm, or logic. If you have one, please open an issue.

    The Economist would also like to acknowledge the many people who have helped us refine the model so far, be it through discussions, facilitating data access, or offering coding assistance. A special thanks to Ariel Karlinsky, Philip Schellekens, Oliver Watson, Lukas Appelhans, Berent Å. S. Lunde, Gideon Wakefield, Johannes Hunger, Carol D'Souza, Yun Wei, Mehran Hosseini, Samantha Dolan, Mollie Van Gordon, Rahul Arora, Austin Teda Atmaja, Dirk Eddelbuettel and Tom Wenseleers.

    All coding and data collection to construct these models (and make them update dynamically) was done by Sondre Ulvund Solstad. Should you have any questions about them after reading the methodology, please open an issue or contact him at sondresolstad@economist.com.

    Suggested citation The Economist and Solstad, S. (corresponding author), 2021. The pandemic’s true death toll. [online] The Economist. Available at: https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates [Accessed ---]. First published in the article "Counting the dead", The Economist, issue 20, 2021.

  10. COVID-19 Trends in Each Country

    • coronavirus-disasterresponse.hub.arcgis.com
    • coronavirus-resources.esri.com
    • +2more
    Updated Mar 28, 2020
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Urban Observatory by Esri (2020). COVID-19 Trends in Each Country [Dataset]. https://coronavirus-disasterresponse.hub.arcgis.com/maps/a16bb8b137ba4d8bbe645301b80e5740
    Explore at:
    Dataset updated
    Mar 28, 2020
    Dataset provided by
    Esrihttp://esri.com/
    Authors
    Urban Observatory by Esri
    Area covered
    Earth
    Description

    On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit: World Health Organization (WHO)For more information, visit the Johns Hopkins Coronavirus Resource Center.COVID-19 Trends MethodologyOur goal is to analyze and present daily updates in the form of recent trends within countries, states, or counties during the COVID-19 global pandemic. The data we are analyzing is taken directly from the Johns Hopkins University Coronavirus COVID-19 Global Cases Dashboard, though we expect to be one day behind the dashboard’s live feeds to allow for quality assurance of the data.DOI: https://doi.org/10.6084/m9.figshare.125529863/7/2022 - Adjusted the rate of active cases calculation in the U.S. to reflect the rates of serious and severe cases due nearly completely dominant Omicron variant.6/24/2020 - Expanded Case Rates discussion to include fix on 6/23 for calculating active cases.6/22/2020 - Added Executive Summary and Subsequent Outbreaks sectionsRevisions on 6/10/2020 based on updated CDC reporting. This affects the estimate of active cases by revising the average duration of cases with hospital stays downward from 30 days to 25 days. The result shifted 76 U.S. counties out of Epidemic to Spreading trend and no change for national level trends.Methodology update on 6/2/2020: This sets the length of the tail of new cases to 6 to a maximum of 14 days, rather than 21 days as determined by the last 1/3 of cases. This was done to align trends and criteria for them with U.S. CDC guidance. The impact is areas transition into Controlled trend sooner for not bearing the burden of new case 15-21 days earlier.Correction on 6/1/2020Discussion of our assertion of an abundance of caution in assigning trends in rural counties added 5/7/2020. Revisions added on 4/30/2020 are highlighted.Revisions added on 4/23/2020 are highlighted.Executive SummaryCOVID-19 Trends is a methodology for characterizing the current trend for places during the COVID-19 global pandemic. Each day we assign one of five trends: Emergent, Spreading, Epidemic, Controlled, or End Stage to geographic areas to geographic areas based on the number of new cases, the number of active cases, the total population, and an algorithm (described below) that contextualize the most recent fourteen days with the overall COVID-19 case history. Currently we analyze the countries of the world and the U.S. Counties. The purpose is to give policymakers, citizens, and analysts a fact-based data driven sense for the direction each place is currently going. When a place has the initial cases, they are assigned Emergent, and if that place controls the rate of new cases, they can move directly to Controlled, and even to End Stage in a short time. However, if the reporting or measures to curtail spread are not adequate and significant numbers of new cases continue, they are assigned to Spreading, and in cases where the spread is clearly uncontrolled, Epidemic trend.We analyze the data reported by Johns Hopkins University to produce the trends, and we report the rates of cases, spikes of new cases, the number of days since the last reported case, and number of deaths. We also make adjustments to the assignments based on population so rural areas are not assigned trends based solely on case rates, which can be quite high relative to local populations.Two key factors are not consistently known or available and should be taken into consideration with the assigned trend. First is the amount of resources, e.g., hospital beds, physicians, etc.that are currently available in each area. Second is the number of recoveries, which are often not tested or reported. On the latter, we provide a probable number of active cases based on CDC guidance for the typical duration of mild to severe cases.Reasons for undertaking this work in March of 2020:The popular online maps and dashboards show counts of confirmed cases, deaths, and recoveries by country or administrative sub-region. Comparing the counts of one country to another can only provide a basis for comparison during the initial stages of the outbreak when counts were low and the number of local outbreaks in each country was low. By late March 2020, countries with small populations were being left out of the mainstream news because it was not easy to recognize they had high per capita rates of cases (Switzerland, Luxembourg, Iceland, etc.). Additionally, comparing countries that have had confirmed COVID-19 cases for high numbers of days to countries where the outbreak occurred recently is also a poor basis for comparison.The graphs of confirmed cases and daily increases in cases were fit into a standard size rectangle, though the Y-axis for one country had a maximum value of 50, and for another country 100,000, which potentially misled people interpreting the slope of the curve. Such misleading circumstances affected comparing large population countries to small population counties or countries with low numbers of cases to China which had a large count of cases in the early part of the outbreak. These challenges for interpreting and comparing these graphs represent work each reader must do based on their experience and ability. Thus, we felt it would be a service to attempt to automate the thought process experts would use when visually analyzing these graphs, particularly the most recent tail of the graph, and provide readers with an a resulting synthesis to characterize the state of the pandemic in that country, state, or county.The lack of reliable data for confirmed recoveries and therefore active cases. Merely subtracting deaths from total cases to arrive at this figure progressively loses accuracy after two weeks. The reason is 81% of cases recover after experiencing mild symptoms in 10 to 14 days. Severe cases are 14% and last 15-30 days (based on average days with symptoms of 11 when admitted to hospital plus 12 days median stay, and plus of one week to include a full range of severely affected people who recover). Critical cases are 5% and last 31-56 days. Sources:U.S. CDC. April 3, 2020 Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Accessed online. Initial older guidance was also obtained online. Additionally, many people who recover may not be tested, and many who are, may not be tracked due to privacy laws. Thus, the formula used to compute an estimate of active cases is: Active Cases = 100% of new cases in past 14 days + 19% from past 15-25 days + 5% from past 26-49 days - total deaths. On 3/17/2022, the U.S. calculation was adjusted to: Active Cases = 100% of new cases in past 14 days + 6% from past 15-25 days + 3% from past 26-49 days - total deaths. Sources: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e4.htm https://covid.cdc.gov/covid-data-tracker/#variant-proportions If a new variant arrives and appears to cause higher rates of serious cases, we will roll back this adjustment. We’ve never been inside a pandemic with the ability to learn of new cases as they are confirmed anywhere in the world. After reviewing epidemiological and pandemic scientific literature, three needs arose. We need to specify which portions of the pandemic lifecycle this map cover. The World Health Organization (WHO) specifies six phases. The source data for this map begins just after the beginning of Phase 5: human to human spread and encompasses Phase 6: pandemic phase. Phase six is only characterized in terms of pre- and post-peak. However, these two phases are after-the-fact analyses and cannot ascertained during the event. Instead, we describe (below) a series of five trends for Phase 6 of the COVID-19 pandemic.Choosing terms to describe the five trends was informed by the scientific literature, particularly the use of epidemic, which signifies uncontrolled spread. The five trends are: Emergent, Spreading, Epidemic, Controlled, and End Stage. Not every locale will experience all five, but all will experience at least three: emergent, controlled, and end stage.This layer presents the current trends for the COVID-19 pandemic by country (or appropriate level). There are five trends:Emergent: Early stages of outbreak. Spreading: Early stages and depending on an administrative area’s capacity, this may represent a manageable rate of spread. Epidemic: Uncontrolled spread. Controlled: Very low levels of new casesEnd Stage: No New cases These trends can be applied at several levels of administration: Local: Ex., City, District or County – a.k.a. Admin level 2State: Ex., State or Province – a.k.a. Admin level 1National: Country – a.k.a. Admin level 0Recommend that at least 100,000 persons be represented by a unit; granted this may not be possible, and then the case rate per 100,000 will become more important.Key Concepts and Basis for Methodology: 10 Total Cases minimum threshold: Empirically, there must be enough cases to constitute an outbreak. Ideally, this would be 5.0 per 100,000, but not every area has a population of 100,000 or more. Ten, or fewer, cases are also relatively less difficult to track and trace to sources. 21 Days of Cases minimum threshold: Empirically based on COVID-19 and would need to be adjusted for any other event. 21 days is also the minimum threshold for analyzing the “tail” of the new cases curve, providing seven cases as the basis for a likely trend (note that 21 days in the tail is preferred). This is the minimum needed to encompass the onset and duration of a normal case (5-7 days plus 10-14 days). Specifically, a median of 5.1 days incubation time, and 11.2 days for 97.5% of cases to incubate. This is also driven by pressure to understand trends and could easily be adjusted to 28 days. Source

  11. COVID-19 mortality rate in Latin America 2023, by country

    • statista.com
    Updated Jun 6, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). COVID-19 mortality rate in Latin America 2023, by country [Dataset]. https://www.statista.com/statistics/1114603/latin-america-coronavirus-mortality-rate/
    Explore at:
    Dataset updated
    Jun 6, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    Latin America, LAC
    Description

    Peru is the country with the highest mortality rate due to the coronavirus disease (COVID-19) in Latin America. As of November 13, 2023, the country registered over 672 deaths per 100,000 inhabitants. It was followed by Brazil, with around 331.5 fatal cases per 100,000 population. In total, over 1.76 million people have died due to COVID-19 in Latin America and the Caribbean.

    Are these figures accurate? Although countries like Brazil already rank among the countries most affected by the coronavirus disease (COVID-19), there is still room to believe that the number of cases and deaths in Latin American countries are underreported. The main reason is the relatively low number of tests performed in the region. For example, Brazil, one of the most impacted countries in the world, has performed approximately 63.7 million tests as of December 22, 2022. This compared with over one billion tests performed in the United States, approximately 909 million tests completed in India, or around 522 million tests carried out in the United Kingdom.

    Capacity to deal with the outbreak With the spread of the Omicron variant, the COVID-19 pandemic is putting health systems around the world under serious pressure. The lack of equipment to treat acute cases, for instance, is one of the problems affecting Latin American countries. In 2019, the number of ventilators in hospitals in the most affected countries ranged from 25.23 per 100,000 inhabitants in Brazil to 5.12 per 100,000 people in Peru.

    For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

  12. Clinical data of COVID-19 infected patients

    • zenodo.org
    • datadryad.org
    bin
    Updated May 15, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Qitian Ou; Wenhong Zhong; Wanjie Zha; Wanjie Zha; Yuan Zhou; Yanmei Zhang; Hongke Zeng; Miaoyun Wen; Qitian Ou; Wenhong Zhong; Yuan Zhou; Yanmei Zhang; Hongke Zeng; Miaoyun Wen (2024). Clinical data of COVID-19 infected patients [Dataset]. http://doi.org/10.5061/dryad.m63xsj49r
    Explore at:
    binAvailable download formats
    Dataset updated
    May 15, 2024
    Dataset provided by
    Zenodohttp://zenodo.org/
    Authors
    Qitian Ou; Wenhong Zhong; Wanjie Zha; Wanjie Zha; Yuan Zhou; Yanmei Zhang; Hongke Zeng; Miaoyun Wen; Qitian Ou; Wenhong Zhong; Yuan Zhou; Yanmei Zhang; Hongke Zeng; Miaoyun Wen
    License

    CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
    License information was derived automatically

    Description

    Objectives

    This study aimed to evaluate the clinical efficacy of Paxlovid in patients hospitalized with severe/critical COVID-19.

    Methods

    Data were acquired from patients with severe/critical COVID-19 diagnosed between December 2022 and January 2023 at a medical center in China. Patients were divided into the Paxlovid treatment group and the conventional treatment group. The association between Paxlovid and all-cause mortality of patients during hospitalization was evaluated using the COX regression model and inverse probability weighting method, respectively. The secondary endpoint was the improvement in patients' lung imaging findings 1 week later. The odds ratio (OR) was estimated using logistic regression.

    Results

    A total of 158 eligible patients were enrolled, including 50 in-hospital deaths (50/98) in the Paxlovid group and 28 (28/60) in the conventional treatment group. The corrected hazard ratio for death was 0.51 (95% CI: 0.28–0.94, p = 0.031) and the inverse probability-weighted hazard ratio was 0.42 (95% CI: 0.24–0.75). The secondary endpoint analysis revealed that Paxlovid was associated with improved lung imaging findings 1 week later (adjusted OR: 0.35, 95% CI: 0.16–0.77).

    Conclusion

    Treatment with Paxlovid is associated with a significantly reduced risk of death and improved lung imaging findings in patients with severe/critical COVID-19.

  13. f

    Estimated counterfactual averted deaths with 80% prediction interval (PI)...

    • plos.figshare.com
    xls
    Updated Apr 16, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Lixin Lin; Haydar Demirhan; Simon P. Johnstone-Robertson; Rajiv Lal; James M. Trauer; Lewi Stone (2024). Estimated counterfactual averted deaths with 80% prediction interval (PI) for each scenario, as described in Part C of the S1 File. [Dataset]. http://doi.org/10.1371/journal.pone.0299844.t001
    Explore at:
    xlsAvailable download formats
    Dataset updated
    Apr 16, 2024
    Dataset provided by
    PLOS ONE
    Authors
    Lixin Lin; Haydar Demirhan; Simon P. Johnstone-Robertson; Rajiv Lal; James M. Trauer; Lewi Stone
    Description

    Estimated counterfactual averted deaths with 80% prediction interval (PI) for each scenario, as described in Part C of the S1 File.

  14. f

    OLS regression results showing associations of selected variables with daily...

    • figshare.com
    xls
    Updated Dec 29, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Taimoor Ahmad; Mujahid Abdullah; Abdul Mueed; Faisal Sultan; Ayesha Khan; Adnan Ahmad Khan (2023). OLS regression results showing associations of selected variables with daily new COVID-19 deaths. [Dataset]. http://doi.org/10.1371/journal.pone.0281326.t003
    Explore at:
    xlsAvailable download formats
    Dataset updated
    Dec 29, 2023
    Dataset provided by
    PLOS ONE
    Authors
    Taimoor Ahmad; Mujahid Abdullah; Abdul Mueed; Faisal Sultan; Ayesha Khan; Adnan Ahmad Khan
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    OLS regression results showing associations of selected variables with daily new COVID-19 deaths.

  15. COVID-19: Predicting 3rd wave in India

    • kaggle.com
    Updated Feb 5, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Aayush Kumar (2022). COVID-19: Predicting 3rd wave in India [Dataset]. https://www.kaggle.com/aayush7kumar/covid19-predicting-3rd-wave-in-india/metadata
    Explore at:
    CroissantCroissant is a format for machine-learning datasets. Learn more about this at mlcommons.org/croissant.
    Dataset updated
    Feb 5, 2022
    Dataset provided by
    Kaggle
    Authors
    Aayush Kumar
    License

    Attribution-NonCommercial-ShareAlike 3.0 (CC BY-NC-SA 3.0)https://creativecommons.org/licenses/by-nc-sa/3.0/
    License information was derived automatically

    Area covered
    India
    Description

    Content

    The WHO coronavirus (COVID-19) dashboard presents official daily counts of COVID-19 cases, deaths and vaccine utilization reported by countries, territories and areas. Through this dashboard, we aim to provide a frequently updated data visualization, data dissemination and data exploration resource, while linking users to other useful and informative resources.

    Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, vaccination strategy, and reporting strategies.

    Acknowledgements

    © World Health Organization 2020, All rights reserved.

    WHO supports open access to the published output of its activities as a fundamental part of its mission and a public benefit to be encouraged wherever possible. Permission from WHO is not required for the use of the WHO coronavirus disease (COVID-19) dashboard material or data available for download. It is important to note that:

    WHO publications cannot be used to promote or endorse products, services or any specific organization.

    WHO logo cannot be used without written authorization from WHO.

    WHO provides no warranty of any kind, either expressed or implied. In no event shall WHO be liable for damages arising from the use of WHO publications.

    For further information, please visit WHO Copyright, Licencing and Permissions.

    Citation: WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https://covid19.who.int/

    Inspiration

    Daily cases start increasing suddenly just before the new year and there's a fear for the upcoming wave. Everybody starts to predict the peak cases in the 3rd wave and the date the peak will be reached. Assume you are in the 1st week of January 2022 and there's panic in the country, for the Omicron variant is said to be highly transmittable. Using your machine learning and deep learning skills, you have to create a model that predicts accurately the peak for the 3rd wave.

  16. Total number of deaths from COVID-19 Indonesia 2023

    • statista.com
    Updated Mar 12, 2020
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2020). Total number of deaths from COVID-19 Indonesia 2023 [Dataset]. https://www.statista.com/statistics/1103816/indonesia-covid-19-number-of-deaths/
    Explore at:
    Dataset updated
    Mar 12, 2020
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    Mar 12, 2020 - Mar 9, 2023
    Area covered
    Indonesia
    Description

    As of March 9, 2023, Indonesia registered 160,941 deaths from the coronavirus. This week, Indonesia is experiencing an increase in cases caused by the highly-contagious Omicron variant.

    For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

  17. u

    Investigation of the sudden unexpected deaths (SUDs) during COVID-19...

    • researchdata.up.ac.za
    xlsx
    Updated Mar 18, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Gadean Brecht (2025). Investigation of the sudden unexpected deaths (SUDs) during COVID-19 pandemic focusing on SARS-CoV-2-positive patients [Dataset]. http://doi.org/10.25403/UPresearchdata.28574498.v1
    Explore at:
    xlsxAvailable download formats
    Dataset updated
    Mar 18, 2025
    Dataset provided by
    University of Pretoria
    Authors
    Gadean Brecht
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    The study included all the deceased participant’s demographics, case history, and SARS-CoV-2 testing results that were entered into an Excel sheet and analyzed using STATA and EpiInfo. Deceased participants were given a unique study identification code. The variables were grouped and presented as frequencies and percentages, with (OR) values comparing the Delta wave period and the Omicron wave period as descriptive statistics. The Odds ratio (OR) of testing positive for SARS-CoV-2 during the two waves associated with sudden and unexpected death as the outcome was calculated using EpiInfo (version 7.2.0.1) Software using Fisher’s exact test. The odds ratios of each variable and the p-value for statistical significance were determined.

  18. Risk of death involving coronavirus (COVID-19) by variant, England

    • ons.gov.uk
    • cy.ons.gov.uk
    xlsx
    Updated Feb 24, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Office for National Statistics (2022). Risk of death involving coronavirus (COVID-19) by variant, England [Dataset]. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/datasets/riskofdeathinvolvingcoronaviruscovid19byvariantengland
    Explore at:
    xlsxAvailable download formats
    Dataset updated
    Feb 24, 2022
    Dataset provided by
    Office for National Statisticshttp://www.ons.gov.uk/
    License

    Open Government Licence 3.0http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
    License information was derived automatically

    Description

    Analysis comparing the risk of coronavirus (COVID-19) death in people infected by Omicron and Delta variants, after adjusting for socio-demographic factors, vaccination status and health conditions.

  19. f

    Table_1_Tracking temporal variations of fatality and symptomology correlated...

    • frontiersin.figshare.com
    docx
    Updated Sep 18, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Shao Lin; Han Liu; Quan Qi; Ian Trees; Donghong Gao; Samantha Friedman; Xiaobo Romeiko Xue; David Lawrence (2024). Table_1_Tracking temporal variations of fatality and symptomology correlated with COVID-19 dominant variants and vaccine effectiveness in the United States.docx [Dataset]. http://doi.org/10.3389/fpubh.2024.1419886.s001
    Explore at:
    docxAvailable download formats
    Dataset updated
    Sep 18, 2024
    Dataset provided by
    Frontiers
    Authors
    Shao Lin; Han Liu; Quan Qi; Ian Trees; Donghong Gao; Samantha Friedman; Xiaobo Romeiko Xue; David Lawrence
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    IntroductionWe described how COVID-19 fatality and symptoms varied by dominant variant and vaccination in the US.MethodsUsing the Restricted Access Dataset from the US CDC (1/1/2020–10/20/2022), we conducted a cross-sectional study assessing differences in COVID-19 deaths, severity indicators (hospitalization, ICU, pneumonia, abnormal X-ray, acute respiratory distress syndrome, mechanical ventilation) and 12 mild symptoms by dominant variant/vaccination periods using logistic regression after controlling for confounders.ResultsWe found the highest fatality during the dominant periods of Wild (4.6%) and Delta (3.4%). Most severe symptoms appeared when Delta was dominant (Rate range: 2.0–9.4%). Omicron was associated with higher mild symptoms than other variants. Vaccination showed consistent protection against death and severe symptoms for most variants (Risk Ratio range: 0.41–0.93). Boosters, especially the second, provided additional protection, reducing severe symptoms by over 50%.DiscussionThis dataset may serve as a useful tool to monitor temporospatial changes of fatality and symptom for case management and surveillance.

  20. f

    Data_Sheet_1_The impact of comorbidity status in COVID-19 vaccines...

    • figshare.com
    zip
    Updated Jun 12, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Maria Elena Camacho-Moll; Viviana Leticia Mata-Tijerina; Carlos Cuauhtémoc Gutiérrez-Salazar; Beatriz Silva-Ramírez; Katia Peñuelas-Urquides; Laura González-Escalante; Brenda Leticia Escobedo-Guajardo; Jorge Eleazar Cruz-Luna; Roberto Corrales-Pérez; Salvador Gómez-García; Mario Bermúdez-de León (2024). Data_Sheet_1_The impact of comorbidity status in COVID-19 vaccines effectiveness before and after SARS-CoV-2 omicron variant in northeastern Mexico: a retrospective multi-hospital study.ZIP [Dataset]. http://doi.org/10.3389/fpubh.2024.1402527.s001
    Explore at:
    zipAvailable download formats
    Dataset updated
    Jun 12, 2024
    Dataset provided by
    Frontiers
    Authors
    Maria Elena Camacho-Moll; Viviana Leticia Mata-Tijerina; Carlos Cuauhtémoc Gutiérrez-Salazar; Beatriz Silva-Ramírez; Katia Peñuelas-Urquides; Laura González-Escalante; Brenda Leticia Escobedo-Guajardo; Jorge Eleazar Cruz-Luna; Roberto Corrales-Pérez; Salvador Gómez-García; Mario Bermúdez-de León
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    IntroductionThe end of the coronavirus disease 2019 (COVID-19) pandemic has been declared by the World Health Organization on May 5, 2023. Several vaccines were developed, and new data is being published about their effectiveness. However, the clinical trials for the vaccines were performed before the Omicron variant appeared and there are population groups where vaccine effectiveness still needs to be tested. The overarching goal of the present study was to analyze the effects of COVID-19 vaccination before and after the Omicron variant in patients considering comorbidities in a population from Nuevo Leon, Mexico.MethodsEpidemiological COVID-19 data from the Mexican Social Security Institute were collected from 67 hospitals located in northeastern Mexico, from July 2020 to May 2023, and a total of 669,393 cases were compiled, 255,819 reported a SARS-CoV-2 positive reverse transcription quantitative polymerase chain reaction (RT-qPCR) test or a positive COVID-19 antigen rapid test.ResultsBefore Omicron (BO, 2020-2021), after 14 days of two doses of COVID-19 vaccine, BNT162b2 and ChAdOx1 vaccines were effective against infection in non-comorbid and all comorbid subgroups, whereas after Omicron (AO, 2022- 2023) there was no significant effectiveness against infection with none of the vaccines. Regarding hospitalization BO, BNT162b2, ChAdOx1, CoronaVac and mRNA-1273 significantly protected non-comorbid patients whereas BNT162b2, ChAdOx1, and mRNA-1273, protected all comorbid subgroups against hospitalization. AO, BNT162b2, ChAdOx1, CoronaVac and mRNA-1273 were effective against hospitalization in non-comorbid patients whereas for most comorbid subgroups BNT162b2, ChAdOx1 and CoronaVac were effective against hospitalization. Non-comorbid patients were protected against death as an outcome of COVID-19 during the BO period with most vaccines whereas a reduction in effectiveness was observed AO with mRNA-1273 vaccines in patients with hypertension, and diabetes mellitus.DiscussionBO, COVID-19 vaccines were effective against infection, hospitalization, and death whereas AO, COVID-19 vaccines failed to protect the population from COVID-19 infection. A varying effectiveness against hospitalization and death is observed AO.

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Statista (2024). COVID-19 cases and deaths per million in 210 countries as of July 13, 2022 [Dataset]. https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/
Organization logo

COVID-19 cases and deaths per million in 210 countries as of July 13, 2022

Explore at:
162 scholarly articles cite this dataset (View in Google Scholar)
Dataset updated
Nov 25, 2024
Dataset authored and provided by
Statistahttp://statista.com/
Area covered
Worldwide
Description

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

Search
Clear search
Close search
Google apps
Main menu